Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New procedure could replace pills for Hormone-Driven high blood pressure

NCT ID NCT05561361

Disease control Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a procedure called superselective adrenal artery embolization can improve blood vessel function in people with primary aldosteronism, a condition where the adrenal glands make too much of the hormone aldosterone, causing high blood pressure. The procedure involves injecting a substance to block part of the adrenal gland, reducing hormone production. Researchers will compare this to standard treatment with the drug spironolactone in 200 adults aged 18-75.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
superselective adrenal artery embolization (a procedure that blocks part of the adrenal gland to reduce hormone secretion)
What this could lead to
If successful, this procedure could offer a less invasive alternative to long-term medication for controlling high blood pressure caused by primary aldosteronism.
What could go wrong
This is a relatively early study with 200 participants, and the procedure carries risks like bleeding or damage to the adrenal gland. It may not prove better than standard drug therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2022

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were diagnosed with primary aldosteronism and underwent adrenal vein sampling at the Second Affiliated Hospital of Nanchang University.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * (1)Aged 18-75 years, males and females; * (2)Blood pressure ≥ 140/90 mmHg on at least three non-same-day office visits without antihypertensive medication or 24-hour ambulatory blood pressure averaging \>130/80 mmHg throughout the day or averaging \>135/85 mmHg during the day; * (3)Primary aldosteronism was diagnosed in accordance with the 2016 international society of Endocrinology clinical guidelines after strict drug elution; * (4)Contraindications to spironolactone-free administration; * (5)No surgical intention or surgical contraindications, and willing to accept drug treatment or percutaneous superselective adrenal artery embolization; * (6)The anatomy of adrenal arteriography is suitable for selective adrenal artery embolization. Exclusion Criteria: * (1)Secondary hypertension of other causes; * (2)Pregnant women or those who have a fertility plan in the next year; * (3)Glomerular filtration rate EGFR \< 45 ml/min/1.73m\^2; * (4)History of severe contrast allergy; * (5)Hyperkalemia; * (6)Patients with other serious organic diseases or life expectancy \< 12 months can not tolerate the treatment of super selective adrenal artery embolizatio; * (7)The diameter of adrenal space occupying lesions was more than 2 cm; * (8)A history of myocardial infarction, syncope, cerebral hemorrhage or cerebral infarction within 3 months before the informed consent; * (9)The results of this study will be affected during the period when patients are enrolled or will participate in other clinical studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary aldosteronism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary aldosteronism

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Second Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.